BCDA stock icon

BioCardia
BCDA

$3.41
7.67%
 

About: BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Employees: 20

0
Funds holding %
of 6,689 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

25% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 4

2.01% less ownership

Funds ownership: 9.52% [Q4 2023] → 7.51% (-2.01%) [Q1 2024]

8% less funds holding

Funds holding: 24 [Q4 2023] → 22 (-2) [Q1 2024]

40% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 5

42% less capital invested

Capital invested by funds: $1.37M [Q4 2023] → $791K (-$574K) [Q1 2024]

Research analyst outlook

1 Wall Street Analyst provided 1 year price forecasts over the past 6 months

Low target
$60
1,660%
upside
Avg. target
$60
1,660%
upside
High target
$60
1,660%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Joseph Pantginis
1,660%upside
$60
Buy
Reiterated
29 May 2024

Financial journalist opinion